Protective Effects of Konjac and Inulin Extracts on Type 1 and Type 2 Diabetes.

Abstract

OBJECTIVE:

The present study was designed to determine whether konjac and inulin extracts or their combination, konjac-inulin (KI) composition, as diet supplementary, can exert beneficial effects against type 1 diabetes and type 2 diabetes using animal models.

METHODS:

A total of 60 diabetic (type 1) rats induced by streptozotocin (STZ) were randomly assigned to five groups: vehicle control (STZ group), KI combination at low dose group (KI-L group), KI combination at medium dose group (KI-M group), KI combination at high dose group (KI-H group), konjac extract group (konjac group), and inulin extract group (inulin group). A sham group (without STZ) was also included. Levels of blood glucose were monitored at each week. After continuous treatment of each diet for 24 days, a glucose tolerance test was performed. After 28 days of treatment, plasma biochemical indicators including glycated serum proteins, total cholesterol, and triglycerides were measured and immunohistochemistry staining of the rat pancreas was performed, to study the insulin expressions. Type 2 diabetes was developed in db/db mice. A total of 28 db/db mice were divided into 4 groups: vehicle control (db/db group), KI composition group (KI group), konjac extract group (konjac group), and inulin extract group (inulin group). A wild-type control group (wild-type group) for db/db mice was also included. Levels of blood glucose, body weight, and blood triglycerides were monitored at each week.

RESULTS:

Daily use of the KI composition significantly decreased levels of blood glucose and blood triglycerides, as well as improved the insulin production in islets or reduced development of obesity in STZ-induced diabetic rats or in db/db mice. Such effects from KI composition were better than single ingredient of konjac or inulin extract.

CONCLUSION:

The results of this study suggest that daily use of KI composition has a protective role on type 1 and 2 diabetes and provided experimental basis for further development of KI composition as a food supplement for diabetic or diabetic high-risk population.

• Authors: Tianle Gao, Yue Jiao, Yang Liu, Tao Li, Zhiguo Wang, Danqiao Wang
• Journal: Journal of diabetes research (J Diabetes Res) Vol. 2019 Pg. 3872182 ( 2019) ISSN: 2314-6753 [Electronic] England
• PMID: 31687407 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 Tianle Gao et al.

Chemical References

• Blood Glucose
• Glycated Hemoglobin A
• Insulin
• Plant Extracts
• Triglycerides
• Inulin
• Cholesterol

Topics

• Amorphophallus
• Animals
• Blood Glucose
• Cholesterol (blood)
• Diabetes Mellitus, Experimental (blood, drug therapy)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Glycated Hemoglobin (metabolism)
• Insulin (blood)
• Inulin (pharmacology, therapeutic use)
• Male
• Mice
• Pancreas (drug effects, metabolism)
• Plant Extracts (pharmacology, therapeutic use)
• Rats
• Rats, Sprague-Dawley
• Triglycerides (blood)